Oncolytics Biotech reports accelerating enrollment in REO 033 Phase 2 trial
Company says randomized REO 033 study is in second-line RAS-mutant, MSS metastatic colorectal cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.